论文部分内容阅读
目的探讨多种血清肿瘤标志物联合检测在肝癌诊断中的临床效果。方法选取2015年1月至2016年12月我院肝癌患者176例、良性肝病患者160例及健康体检者160例,空腹静脉抽血5mL,进行甲胎蛋白(AFP)、谷氨酰转移酶(GGT)、糖类抗原125(CA125)、α-L-岩藻糖苷酶(AFU)检测,比较各组患者各检测指标水平,并记录上述血清指标联合检测肝癌的阳性检出率。结果肝癌组AFP、GGT、CA125、AFU水平均高于良性肝病组和健康体检组(P<0.05);血清AFP、GGT、CA125、AFU联合检测肝癌阳性检出率明显高于任何单一检测指标(P<0.05)。结论在肝癌疾病诊断中,采取多种血清肿瘤标志物联合检测能显著提高其阳性检出率,具有良好的临床诊断价值。
Objective To explore the clinical effect of combined detection of multiple serum tumor markers in the diagnosis of liver cancer. Methods From January 2015 to December 2016, 176 patients with HCC, 160 patients with benign liver disease and 160 healthy subjects were enrolled in this study. Fasting venous blood was drawn from 5 mL for AFP and glutamyl transferase (GGT), carbohydrate antigen 125 (CA125) and α-L-fucosidase (AFU). The positive rate of the detection of hepatocellular carcinoma by the above serum markers was recorded. Results The levels of AFP, GGT, CA125 and AFU in hepatocellular carcinoma group were significantly higher than those in benign liver disease group and healthy group (P <0.05). The detection rates of AFP, GGT, CA125 and AFU in hepatocellular carcinoma were significantly higher than those in any single detection group P <0.05). Conclusion In the diagnosis of liver cancer, the combined detection of multiple serum tumor markers can significantly increase the positive detection rate, which has a good clinical diagnostic value.